

July 5, 2021

S.C.L.M. Cremers, PhD, PharmD
Editor-in-Chief
British Journal of Clinical Pharmacology

Dear Dr. Cremers:

We are submitting this review article *‘Translational and Clinical Pharmacology Considerations in Drug Repurposing for X-linked Adrenoleukodystrophy-A Rare Peroxisomal Disorder’* in response to an invitation from Dr. Mifsud for the upcoming thematic issue on rare diseases. All coauthors fulfil the criteria for authorship and have seen and agree with the contents of the manuscript. We confirm that the submission is not under review at any other publication.

The manuscript has three components: 1) a review of adrenoleukodystrophy (ALD), a rare disease, written at the generalist level, 2) an overview of repurposed drugs that have/are being studied for treatment of ALD, and 3) a brief consideration of how application of the principles of translational and clinical pharmacology early in the process of drug development can facilitate research and, potentially, improve the probability of a successful outcome.

Thank you for your consideration of our work. We have prepared this manuscript as per this journal’s guidelines. We eagerly await comments from the reviewers and will be happy to address suggestions and critical comments.

Thank you,

Sincerely,


James Cloyd


Reena Kartha (Corresponding author)

University of Minnesota Department of Experimental and Clinical Pharmacology
4-214 McGuire Translational Research Facility
2001, 6th Street SE Minneapolis, MN 55455
Ph: 612-626-2436
Email: rvkartha@umn.edu
Fax: 612-626-9985